Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients—specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant patients, and head and neck cancer patients—its use remains controversial and is not recommended for the majority of patients with cancer-associated weight loss. Most patients with advanced cancer, anorexia, and/or weight loss do not appear to benefit from nutritional supplementation. Instead, discussions with patients and families about realistic eating goals and, at times, pharmacologic interventions with progestational agents or corticosteroids—both of which are aimed at palliating anorexia—provide clinical benefit. Other pharmacologic interventions such as eicosapentaenoic acid, thalidomide (Thalomid), adenosine triphosphate, and nonsteroidal anti-inflammatory agents focus on the fact that cancer-associated weight loss is an entity distinct from simple starvation. These interventions promise to replenish lean tissue but require further investigation before they can be recommended as standard clinical practice.
Loss of weight and appetite predict a poor prognosis for cancer patients. In an 1811 treatise, John Abernathy described a patient with a tumor, "which made him look very sickly and grow very thin, and caused some persons to deem the disease cancerous." Abernathy went on to say that "the derangement of the constitution was as violent as the local disease, and in about a week, the patient died."
Spurred by such early observations, DeWys and others formally analyzed the impact of weight loss on cancer prognosis. In a multi-institutional, retrospective, Eastern Cooperative Oncology Group evaluation of 3,047 patients from 12 different clinical trials, these investigators found that loss of more than 5% of premorbid weight predicted a poor prognosis for cancer patients. Independent of tumor stage, tumor histology, and patient performance status, this weight loss not only predicted a poor outcome but was associated with a trend toward lower chemotherapy response rates.
Along similar lines, Chang recently reviewed the prognostic effect of various cancer symptoms. He summarized studies showing that loss of appetite also predicts a poor outcome for cancer patients. Taken together, these three publications demonstrate a strong association between cancer-associated anorexia/weight loss and an early demise.
Couple these prognostic data with the observation that cancer-associated anorexia and weight loss are highly prevalent, and the magnitude of the problem enlarges. Tchekmedyian and others examined the prevalence of cancer-associated weight loss and anorexia in an ambulatory oncology setting. Among 644 consecutive patients, evidence of diminished appetite, compromised oral intake, or weight loss greater than 5% of premorbid weight occurred in more than half of patients. Additionally, 54% of patients were underweight in direct comparisons between patients’ actual weight and calculated ideal weight. These prevalence rates are likely to be even higher among nonambulatory cancer patients in the late stages of advanced disease. In short, cancer-associated anorexia and weight loss are common and carry a notable adverse prognostic impact.
Almost 200 years after Abernathy’s description of his patient with a "derangement of the constitution," weight loss continues to plague cancer patients. Yet, treatment has yielded only modest success. Clinical efforts have primarily focused on energy repletion by means of either a direct increase in caloric intake or mitigation of anorexia. Only more recently have treatment efforts targeted maintenance of lean tissue. Below, we summarize treatment approaches for cancer-associated weight loss and anorexia and the rationale for their use, as they pertain to (1) caloric supplementation, (2) orexigenic agents, and (3) agents targeted at maintenance of lean tissue.
Role of Caloric Supplementation
At first glance, caloric repletion seems the optimal approach to the treatment of cancer-associated weight loss. After all, since weight loss is the result of an energy deficit, an increase in caloric intake would appear to tilt the scales in favor of weight stability and, thereby, generate clinical benefit for cancer patients. Studies have suggested, however, that increased caloric intake might help cancer patients in only a few specific circumstances: (1) perioperatively, (2) in the setting of stem cell or bone marrow transplantation, and (3) during treatment for head and neck cancer.
The data to support these indications are discussed below (Table 1). Otherwise, caloric supplementation either has not been tested or has proven to be detrimental.
Perioperative Nutritional Support: First, two studies suggest perioperative nutritional support benefits patients prior to major surgery, counterbalanced by one recent meta-analysis on total parenteral nutrition in general. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group trial examined 395 malnourished patients who were randomized to receive no fewer than 7 days of standard preoperative total parenteral nutrition vs no nutritional supplementation. All patients were considered surgical candidates prior to study enrollment, and 65% had cancer.
Within this study, the 24 patients who were considered severely malnourished, as suggested by low scores on the Nutrition Risk Index, appeared to benefit from perioperative nutritional support. These patients manifested fewer noninfectious complications—such as anastomotic leak, bronchopleural fistula, and others—when compared to severely malnourished patients who did not receive nutritional support. Such benefits were not observed among patients with mild or moderate malnutrition.
Similarly, in the second trial, Fan et al evaluated 124 malnourished patients with hepatocellular carcinoma prior to surgery. Many of these patients were only mildly malnourished, with only 20% having sustained a loss of > 10% of their premorbid weight. In this placebo-controlled, randomized trial, patients who received total parenteral nutrition sustained an overall reduction in postoperative morbidity. There was also a reduction in the use of diuretics in the postoperative setting. Although neither of these studies showed a survival advantage with total parenteral nutrition, they did demonstrate a decrease in morbidity.
In contrast to these two studies, a recent meta-analysis, which included 26 randomized trials and a total of 2,211 patients, concluded that the use of total parenteral nutrition in surgical or critically ill patients did not improve mortality or complication rates. Although not all studies in this meta-analysis included cancer patients, the comprehensiveness of the analysis and the fact that some cancer patients were included suggest that the use of total parenteral nutrition for cancer patients perioperatively should be weighed carefully prior to implementation.
Taken together, these data support caloric supplementation in the perioperative setting among cancer patients with severe malnutrition or in patients with a potentially resectable hepatocellular carcinoma, although such recommendations remain controversial.
Enteral and Parenteral Nutrition: Secondly, nutritional supplementation potentially helps patients in the setting of stem cell rescue after high-dose chemotherapy. Both enteral and parenteral nutrition appear to be beneficial.
In one of the earliest and largest studies examining total parenteral nutrition in the transplant setting, Weisdorf et al evaluated 137 patients who were well nourished at the initiation of their transplant procedure. The majority of these patients (93%) had been diagnosed with cancer, predominantly leukemia. After stratification on the basis of age and type of transplant (autologous vs allogeneic), patients were randomized to receive either total parenteral nutrition or intravenous fluids with 5% dextrose, electrolytes, minerals, trace elements, vitamins, and no lipids. Both treatment arms were initiated prophylactically—ie, prior to patients showing evidence of malnutrition. Because a decline in nutritional status became evident during the clinical course of these patients, 61% in the control arm crossed over to the total parenteral nutrition arm.
In a direct comparison of the two study arms, overall survival, time to cancer relapse, and disease-free survival were significantly improved in the total parenteral nutrition arm. In contrast, the incidence of graft-vs-host disease, time to engraftment, and time to bacteremia were not significantly different between the two arms. In effect, this study suggests that total parenteral nutrition confers some benefit in this setting when administered prophylactically.
Head and Neck Cancer: Thirdly, studies in patients with head and neck cancer also suggest a role for nutritional supplementation, although these studies are far less compelling than the studies cited above. In one preliminary trial, 40 patients with inoperable nasopharyngeal or oropharyngeal squamous cell carcinoma were randomized to receive either oral nutrition or intensive nasogastric tube feedings during radiation treatment. The latter provided more calories.
Although no statistical differences were observed between the two groups with respect to tumor response rates or survival, a slightly greater percentage of patients who received the tube feedings—8 of 13 tube-fed patients vs 5 of 11 orally fed patients—returned to their regular activities after a 6-month follow up period. These data might be viewed as exploratory in nature, but they nevertheless suggest that aggressive oral nutrition might confer clinical benefit to head and neck cancer patients during aggressive therapy.
Similarly, another randomized trial by Nayel and others found that aggressive oral feeding resulted in completion of radiation without interruption in 11 of 11 patients who received it. In contrast, radiation therapy was interrupted in 5 of 12 patients who did not receive aggressive oral feeding. These data suggest that aggressive feeding might provide short- and long-term benefits to head and neck cancer patients.
Advanced Cancer: In contrast to the specific clinical indications sited above, trials in chemotherapy patients with advanced cancer have not demonstrated favorable outcomes with aggressive caloric supplementation. In one such study, Ovesen et al evaluated 105 cancer patients who were receiving chemotherapy. Patients were randomized to either nutritional counseling or no nutritional counseling. Although the former group consumed significantly more calories than the latter group, tumor response rates, patient survival, and quality of life did not differ significantly between the two groups.
Several clinical trials in which patients with advanced cancer received total parenteral nutrition also failed to demonstrate a favorable impact of nutritional supplementation. Some of these studies actually noted increased rates of infection or other detrimental effects with the use of total parenteral nutrition.
Recommendations: In 1989, a review of these studies led to a consensus statement from the American College of Physicians (ACP) on total parenteral nutrition in cancer patients receiving chemotherapy. More than 10 years later, the ACP has not revised their original statement:
The routine use of parenteral nutrition for patients undergoing chemotherapy should be strongly discouraged, and, in deciding to use such therapy in individual patients whose malnutrition is judged to be life threatening, physicians should take into account the possible exposure to increased risk.
How do we reconcile the results of the foregoing studies, some of which suggest clinical benefits with nutritional supplementation in cancer patients, and others of which do not? Moreover, since not all groups of cancer patients have been formally studied with respect to implementation of adjunctive nutritional therapy, how do we decide when to use such supportive measures and when not to?
Two empiric guidelines, derived from the studies cited above, might help answer these questions. Cancer patients who seem to benefit from caloric supplementation fall into both of the following categories: (1) patients who are either notably malnourished or at risk of becoming so during cancer treatment; and (2) patients who have potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment.
In summary, reasonable justification can be found for administering adjunctive nutritional therapy to cancer patients prior to an attempt at resecting the primary tumor, prophylactically during stem cell or bone marrow transplantation, and during radiation treatment for head and neck cancer. With malignancies such as potentially curative locally advanced esophageal cancer treated with concomitant chemotherapy and radiation, the use of adjunctive nutritional therapy remains of speculative value and must be decided on a case-by-case basis. In contrast, little justification exists for the use of adjunctive nutritional treatment, such as total parenteral nutrition, in patients receiving chemotherapy for advanced cancer.
1. Abernathy J: Surgical Observations of Tumours, and on Lumbar Abscesses. London, Longman, Hurst, Rees, Orme, and Brown, Paternoster-Row, 1811.
2. Dewys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497, 1980.
3. Chang VT: The value of symptoms in prognosis of cancer patients, in Portenoy RK, Bruera E (eds): Topics in Palliative Care, vol 4. New York, Oxford University Press, 2000.
4. Tchekmedyian NS: Costs and benefits of nutrition support in cancer. Oncology 9(suppl 11):79-84, 1995.
5. Veterans Affairs Total Parenteral Nutrition Cooperative Study Group: Perioperative total parenteral nutrition in surgical patients. N Engl J Med 325:525-532, 1991.
6. Fan ST, Lo M, Lai ECS, et al: Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 331:1547-1552, 1994.
7. Hetland DK, MacDonald S, Keefe L, et al: Total parenteral nutrition in the critically ill patient. JAMA 280:2013-2019, 1998.
8. Weisdorf SA, Lysne J, Wind D, et al: Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 43:833-838, 1987.
9. Daly JM, Hearne B, Dunaj J, et al: Nutritional rehabilitation in patients with advanced head and neck cancer receiving radiation therapy. Am J Surg 148:514-520, 1984.
10. Nayel H, el-Ghoneimy E, el-Haddad S: Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. Nutrition 8:13-28, 1992.
11. Ovesen L, Allingstrup L, Hannibal J, et al: Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol 11:2043-2049, 1993.
12. American College of Physicians: Parenteral nutrition in patients receiving cancer chemotherapy. Ann Intern Med 110:734-736, 1989.
13. Walsh D, Donnelly S, Rybicki L: The symptoms of advanced cancer: Relation to age, gender, and performance status in 1000 patients. Support Care Cancer 8:175-179, 2000.
14. Jatoi A, Kumar S, Sloan J, Nguyen PL: On appetite and its loss. J Clin Oncol 18:2930-2932, 2000.
15. Loprinzi CL, Ellison NM, Schaid DJ, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132, 1990.
16. Loprinzi CL, Bernath AM, Schaid DJ, et al: Phase III evaluation of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology 51(suppl 1):2-7, 1994.
17. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607-1609, 1974.
18. Loprinzi CL, Kugler JW, Sloan JA, et al: Randomized comparison of megestrol acetate vs dexamethasone vs fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299-3306, 1999.
19. Lissoni P, Paolorossi F, Tancini G, et al: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A:1340-1343, 1996.
20. Kardinal CG, Loprinzi CL, Schaid DJ, et al: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657-2662, 1990.
21. Goldberg RM, Loprinzi CL, Mailliard JA, et al: Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13:2856-2859, 1995.
22. Cohn SH, Gartenhaus W, Sawitsky A, et al: Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism 30:222-229, 1981.
23. Keys A, Brozek, J, Henschel A, et al: The Biology of Human Starvation. St. Paul, Minnesota, The University of Minnesota Press, 1950.
24. Jatoi A, Daly BDT, Hughes VA, et al: Do patients with early-stage non-small-cell lung cancer suffer cancer cachexia (abstract 171)? Proc Am Soc Clin Oncol 17:44a, 1998.
25. Staal-van den Brekel AJ, Shols AMW, ten Velde GPM, et al: Analysis of the energy balance in lung cancer patients. Cancer Res 54:6430-6433, 1994.
26. Stallings VA, Vaisman N, Chan HS, et al: Energy metabolism in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Res 26:154-157, 1989.
27. Peacock JL, Inculet RI, Corsey R, et al: Resting energy expenditure and body cell mass alterations in noncachectic patients with sarcomas. Surgery 102:465-472, 1987.
28. Dempsey DT, Knox LS, Mullen JL, et al: Energy expenditure in malnourished patients with colorectal cancer. Arch Surg 121:789-795, 1986.
29. Bing C, Brown M, King P, et al: Increased gene expression of brown fat uncoupling protein (UCP) 1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 60:2405-2410, 2000.
30. Todorov P, Cariuk P, McDevitt T, et al: Characterization of a cancer cachectic factor. Nature 379:739-742, 1996.
31. Hellerstein MK, Meydani SN, Meydani M, et al: Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 84:228-235, 1989.
32. Falconer JS, Fearon KC, Plester CE, et al: Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325-331, 1994.
33. Ling PR, Schwartz JH, Bistrian BR: Mechanisms of host wasting induced by administration of cytokines in rats. Am J Phys 272(3 Pt 1):E333-339, 1997.
34. Fong Y, Moldawer LL, Marano M, et al: Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Phys 256(3 Pt 2):R659-665, 1989.
35. Greenberg AS, Nordan RP, McIntosh J, et al: Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: A possible role for interleukin 6 in cancer cachexia. Cancer Res 52:4113-4116, 1992.
36. Llovera M, Carbo N, Lopez-Soriano J, et al: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133:83-87, 1998.
37. Barber MD, McMillan DC, Preston T, et al: Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci 98:389-399, 2000.
38. Wigmore SJ, Barber MD, Ross JA, et al: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177-184, 2000.
39. Gogos CA, Ginopoulos P, Salsa B, et al: Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial. Cancer 82:395-402, 1998.
40. Hussey HJ, Tisdale MJ: Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br J Cancer 80:1231-1235, 1999.
41. Boasberg PD, O’Day SJ, Weisberg M, et al: Thalidomide induced cessation of weight loss and improved sleep in advanced cancer patients with cachexia (abstract 2396). Proc Am Soc Clin Oncol 19:609a, 2000.
42. Agteresch HJ, Dagnelie PC, van der Gaast A, et al: Randomized clinical trial of adenosine 5’-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321-328, 2000.
43. McMillan DC, Wigmore SJ, Fearon KC, et al: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer in patients with weight loss. Br J Cancer 79:495-500, 1999.
44. McMillan DC, O’Gorman P, Fearon KC, et al: A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 76:788-790, 1997.